Conference
Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)
Authors
Hughes TP; Cervantes F; Spector N; Leber B; Branford S; Glynos TA; Acharya S; Dalal D; Lipton JH
Volume
126
Publisher
AMER SOC HEMATOLOGY
Publication Date
December 3, 2015
Name of conference
57th Annual Meetings and Exposition of the American-Society-of-Hematology
Conference place
FL, Orlando
Conference start date
December 4, 2015
Conference end date
December 8, 2015
Conference proceedings
BLOOD
Issue
23
ISSN
0006-4971